age at first encounter was 64 years (range:29-96); 54% were female and 54% Asian. Median time from diagnosis of stage IV NSCLC to first encounter was 23 months (range:0-67). The median number of HUS collected per patient was 2 (range:1-14). For patients with multiple visits the median time between completed questionnaires was 1.8 months (1)(2)(3)(4)(5)(6)(7)(8)(9)(10)(11)(12)(13)(14)(15)(16)(17)(18). 105 patients (43%) presented with or developed brain metastases during the study period. In a univariable analysis, regardless of treatment line, mean HUS (mHUS) on osimertinib was 0.85 (standard deviation (SD):0.15) (n¼33 patients; 114 encounters) compared to mHUS¼0.80 (SD:0.17) on gefitinib (n¼147, 351 encounters); mHUS¼0.72 (SD:0.16) on chemotherapy (n¼32, 76 encounters); and mHUS¼0.79 (SD¼0.15) on other TKIs (n¼49, 133 encounters); p<0.001. In a multivariable analysis, disease progression (p¼0.04) and ECOG performance status >0 (p<0.001) were associated with lower HUS. In contrast, treatment with osimertinib (when compared to a reference group of first-generation TKIs, gefitinib/erlotinib) was associated with improved HUS (p¼0.01), while line of therapy and number of metastatic sites of disease were not associated with HUS. In addition, brain metastases had no significant impact on HUS (p¼0.33). Conclusion: Progressive disease and worse performance status associate with lower HUS in patients with EGFRm NSCLC. Patients treated with osimertinib had the highest HUS when compared with a reference group of first-generation EGFR TKIs regardless of line of therapy. These results may help in the choice of EGFR-TKI, especially in patients with a poor performance status.
Background: Checkpoint immunotherapy (IO) is revolutionizing NSCLC therapy. We have previously published results of an online decision support tool designed to provide clinicians with education and expert guidance (Chow et al: JTO 2015) . Here we report an analysis of a recently updated version of this online tool, capturing the impact of emerging IO options. Method: From June 2016 to July 2017, the NSCLC decision tool was updated to incorporate new treatment options for 280 different case scenarios. Briefly, oncologists entered patient and disease characteristics and then their planned treatment into the tool. Afterwards recommendations from 5 lung cancer experts were provided for that specific patient scenario. Result: This analysis includes 1481 individual cases entered by 863 practicing oncologists between June 2016 and April 2018 (USA 19%, Europe 33%, Rest of World 48%). During this time, treatment choices for EGFR and ALK cancers by oncologists closely resemble those of experts. After approval of 1st-line pembrolizumab for patients with high PD-L1 expression, oncologists recommended pembrolizumab less often than experts (67% vs 95%). In the 2nd-line setting following platinum chemotherapy, both tumor histology and PD-L1 expression level impacted treatment recommendations (see Table) . For PD-L1 expression < 1%, recommendations between oncologists and experts differed substantially. Conclusion: This updated analysis of an online NSCLC decision-making tool integrates recent changes to the treatment landscape in 2017, capturing emerging patterns in IO therapy. Compared to earlier versions, practicing oncologist's choice of 1st-line EGFR-and ALK-targeted therapy more closely tracked with experts during this period, while selection of IO differs from expert recommendations. A detailed analysis of expert versus online user data will be presented. We report the establishment of a national audit of outcomes after lung cancer resection (LCCOP) in the English National Health Service (NHS), a government healthcare system providing the great majority of lung cancer surgery. LCCOP is a compulsory audit commissioned by NHS England. Method: Unusually, for a surgical audit, data is initially obtained from the cancer registry, and matched to national Hospital Episode Data (HES), before local validation by clinical teams. After case mix adjustment, unit level survival rates at 30, 60 and 90 days, and length-of-stay data are published online and in an annual report. The first annual report was released in 2014. Survival is adjusted for age, sex, performance status, stage, laterality, FEV1 percentage, comorbidity and socioeconomic status Result: The number of resections rose by 21% between 2015-2017 (4892 to 5936). Median annual activity per surgeon rose from 30 to 49 cases between 2014-2017, a 63% increase. In 2015 survival at 30, 90 and 365 days was 98.1%, 96.3% and 87.9% respectively. Median length of stay was 6 days (IQR 4-9 Background: Tumor PD-L1 expression has been shown to enrich for response to immunotherapy in several indications, including advanced NSCLC. However, the stability of PD-L1 expression over time and its relationship with non-immunotherapy cancer treatment is currently uncertain. We hypothesized that prior chemotherapy or radiotherapy would increase PD-L1 expression. Method: In the Phase 2, open-label, single-arm durvalumab ATLANTIC study (NCT02087423), patients who had received 2 prior systemic regimens in the treatment of Stage IIIB or IV NSCLC were screened for tumor PD-L1 expression by immunohistochemistry using the VENTANA PD-L1 (SP263) Assay (25% tumor cell [TC] cutoff). PD-L1 expression was assessed using either a recent (<3 months) or archival sample; a subset of patients provided both. The relationship between non-immunotherapy cancer treatment and prevalence of tumor PD-L1 expression 25% (TC25%) was assessed in patients who received therapy prior to sample acquisition versus those who did not. Pearson's chi-squared test was used to examine the differences between patient subgroups. Result: Of the patients screened for participation in ATLANTIC, 1590 were successfully assessed for PD-L1 expression. PD-L1 TC25% prevalence was higher in patients who had received prior radiotherapy or chemotherapy before sample acquisition, with prevalence noticeably higher in those who had received 2 lines of prior chemotherapy. Prior EGFR inhibitor treatment did not have any noticeable relationship to TC25% prevalence (Table) . In the subset of patients with paired recent and archival samples, TC25% prevalence remained the same in 74% of cases, increased over time in 19.5%, and decreased in 6.5%. Conclusion: PD-L1 expression may increase in response to chemotherapy or radiotherapy and is unlikely to decrease over time. Re-biopsy may provide a more accurate assessment of current tumor PD-L1 expression status when a low/negative result is seen in an archival sample, particularly if the patient has received multiple lines of intervening radiotherapy or chemotherapy. Keywords: programmed cell death ligand-1, Diagnostic test, Immunotherapy 
